Clinical trial
A Phase Ⅰ Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of QL1706H in Advanced Solid Tumors
NCT06047431 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ⅰ Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of QL1706H in Advanced Solid Tumors
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- October 31, 2023
- Completion date
- December 31, 2025
- Enrollment
- 150 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumors